1. Home
  2. TENB vs IMNM Comparison

TENB vs IMNM Comparison

Compare TENB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenable Holdings Inc.

TENB

Tenable Holdings Inc.

HOLD

Current Price

$33.50

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$21.45

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENB
IMNM
Founded
2002
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
TENB
IMNM
Price
$33.50
$21.45
Analyst Decision
Buy
Strong Buy
Analyst Count
18
10
Target Price
$31.69
★ $32.80
AVG Volume (30 Days)
★ 5.3M
975.9K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
3.23
★ 51.40
EPS
★ 0.05
N/A
Revenue
★ $999,405,000.00
$6,941,000.00
Revenue This Year
$9.37
N/A
Revenue Next Year
$7.04
$1,127.34
P/E Ratio
$717.60
★ N/A
Revenue Growth
★ 11.04
N/A
52 Week Low
$15.73
$11.09
52 Week High
$43.67
$30.06

Technical Indicators

Market Signals
Indicator
TENB
IMNM
Relative Strength Index (RSI) 45.87 31.21
Support Level $30.97 $19.39
Resistance Level $39.26 $23.25
Average True Range (ATR) 2.20 1.19
MACD 0.03 -0.42
Stochastic Oscillator 44.39 1.42

Price Performance

Historical Comparison
TENB
IMNM

About TENB Tenable Holdings Inc.

Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: